Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financi...(from continuing operations (25200...),Health

Date:2/25/2009

from continuing operations (25,200) (23,556) (89,011) (69,174) Investment income (expense), net (558) 1,926 1,146 8,755 Other income (expense), net 67 (119) (393) (543) Loss from continuing operations before income taxes (25,691) (21,749) (88,258) (60,962) Income tax benefit (1,344) (4,634) (5,017) (11,807) Loss from continuing operations (24,347) (17,115) (83,241) (49,155) Income (loss) from discontinued operations, net of taxes 142 487 (928) 487 Net loss $(24,205) $(16,628) $(84,169) $(48,668) Loss per common share, from continuing operations: Basic and diluted $(0.45) $(0.32) $(1.55) $(0.94) Earnings (loss) per common share, from discontinued operations: Basic and diluted $- $0.01 $(0.02) $0.01 Loss per common share: Basic and diluted $(0.45) $(0.31) $(1.57) $(0.93) Weighted average number of common and common equivalent shares: Basic and diluted 53,694 52,815 53,533 52,461

'/>"/>

SOURCE Savient Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
4. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
5. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
6. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
7. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
8. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
9. Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
10. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
11. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results